DK3110840T3 - A22k, desb27, b29r, des b30, ved epsilon-position af lysin 22 acyleret human insulinanalog - Google Patents

A22k, desb27, b29r, des b30, ved epsilon-position af lysin 22 acyleret human insulinanalog Download PDF

Info

Publication number: DK3110840T3
Authority: DK; Denmark
Prior art keywords: desb27; lysin; des; human insulin; insulin analog
Prior art date: 2014-02-28

Application number

DK15707102.8T

Other languages

English (en)

Inventor

Susanne Hostrup

Martin Münzel

Claudia Ulrich Hjørringgaard

Christian Fledelius

Peter Madsen

Thomas Børglum Kjeldsen

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-02-28

Filing date

2015-02-26

Publication date

2020-11-02

2015-02-26 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2020-11-02 Application granted granted Critical

2020-11-02 Publication of DK3110840T3 publication Critical patent/DK3110840T3/da

Links

101150019032 B29R gene Proteins 0.000 title 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 title 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Hematology (AREA)
Obesity (AREA)
Immunology (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Oil, Petroleum & Natural Gas (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)

DK15707102.8T 2014-02-28 2015-02-26 A22k, desb27, b29r, des b30, ved epsilon-position af lysin 22 acyleret human insulinanalog DK3110840T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP14157215		2014-02-28
PCT/EP2015/053989 WO2015128403A2 (en)	2014-02-28	2015-02-26	Novel insulin derivatives and the medical uses hereof

Publications (1)

Publication Number	Publication Date
DK3110840T3 true DK3110840T3 (da)	2020-11-02

Family

ID=50184804

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK15707102.8T DK3110840T3 (da)	2014-02-28	2015-02-26	A22k, desb27, b29r, des b30, ved epsilon-position af lysin 22 acyleret human insulinanalog

Country Status (23)

Country	Link
US (1)	US10040839B2 (da)
EP (1)	EP3110840B1 (da)
JP (1)	JP6580583B2 (da)
KR (1)	KR20160125988A (da)
CN (1)	CN106459171B (da)
AR (1)	AR099569A1 (da)
AU (1)	AU2015222135B2 (da)
BR (1)	BR112016017193A2 (da)
CA (1)	CA2941103A1 (da)
DK (1)	DK3110840T3 (da)
ES (1)	ES2831848T3 (da)
HR (1)	HRP20201732T1 (da)
HU (1)	HUE051355T2 (da)
IL (1)	IL246757B (da)
MX (1)	MX368387B (da)
PL (1)	PL3110840T3 (da)
PT (1)	PT3110840T (da)
RS (1)	RS61137B1 (da)
RU (1)	RU2684456C2 (da)
SA (1)	SA516371705B1 (da)
SI (1)	SI3110840T1 (da)
TW (1)	TWI686403B (da)
WO (1)	WO2015128403A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3113791B1 (en) *	2014-03-07	2018-12-26	Jørgensen, Klavs Holger	Novel fast acting insulin preparations
AR106364A1 (es)	2015-08-25	2018-01-10	Novo Nordisk As	Derivados de insulina y sus usos médicos
CA3044565A1 (en) *	2016-11-21	2018-05-24	Case Western Reserve University	Rapid-acting insulin analogues of enhanced stability
KR101909052B1 (ko) *	2017-02-09	2018-10-17	강원대학교산학협력단	인슐린의 a 사슬로부터 유래된 펩타이드 단편 및 이를 포함하는 당뇨병 또는 당뇨병성 창상의 예방 또는 치료용 약학 조성물
MA49339A (fr) *	2017-04-05	2020-02-12	Novo Nordisk As	Conjugués insuline-fc à extension oligomère
JOP20190273A1 (ar) *	2017-05-26	2019-11-24	Lilly Co Eli	مركب إنسولين معالج بأسيل
TW201917134A (zh) *	2017-08-17	2019-05-01	丹麥商諾佛儂迪克股份有限公司	新穎的醯基化胰島素類似物及其用途
IL274002B2 (en) *	2017-10-19	2026-03-01	Mona E Buice	A topical preparation for improved healing of open wounds
US11965039B2 (en)	2018-02-27	2024-04-23	Zp Spv 3 K/S	Compstatin analogues and their medical uses
TWI829687B (zh) *	2018-05-07	2024-01-21	丹麥商諾佛儂迪克股份有限公司	包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2020120477A1 (en)	2018-12-11	2020-06-18	Sanofi	Insulin analogs having reduced insulin receptor binding affinity
US12178879B2 (en)	2019-02-13	2024-12-31	Sumitomo Pharma Co., Ltd.	Hemiasterlin derivative and antibody-drug conjugate thereof
US12312419B2 (en)	2019-02-13	2025-05-27	Sumitomo Pharma Co., Ltd.	Hemiasterlin derivative having cysteine residue
CN114630836A (zh) *	2019-08-27	2022-06-14	西兰制药第三特殊目的公司	补体抑制素类似物及其医学用途
DK4073097T3 (da)	2019-12-11	2024-08-19	Novo Nordisk As	Nye insulinanaloger og anvendelser heraf
CN118420744A (zh) *	2019-12-30	2024-08-02	甘李药业股份有限公司	胰岛素衍生物
EP4347632A4 (en) *	2021-05-24	2025-03-26	Sunshine Lake Pharma Co., Ltd.	A novel acylated insulin analog

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3528960A (en)	1968-10-07	1970-09-15	Lilly Co Eli	N-carboxyaroyl insulins
US3869437A (en)	1970-05-08	1975-03-04	Nat Res Dev	Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
GB1381274A (en)	1971-01-28	1975-01-22	Nat Res Dev	Insulin derivatives
US3864325A (en)	1971-11-18	1975-02-04	Nat Res Dev	(N{HU Al{b , N{HU Bl{b , N{HU B29{B , carbamoyl)-(O{HU A14{B , O{HU B16{B , O{HU B26{B aryl) insulin derivatives
JPH01254699A (ja)	1988-04-05	1989-10-11	Kodama Kk	インスリン誘導体及びその用途
AU641631B2 (en) *	1988-12-23	1993-09-30	Novo Nordisk A/S	Human insulin analogues
CA2070814A1 (en) *	1989-12-21	1991-06-22	Klavs H. Jorgensen	Insulin preparations containing nicotinic acid or nicotinamide
SI0792290T1 (en)	1993-09-17	2001-12-31	Novo Nordisk As	Acylated insulin
US6869930B1 (en)	1993-09-17	2005-03-22	Novo Nordisk A/S	Acylated insulin
US6011007A (en)	1993-09-17	2000-01-04	Novo Nordisk A/S	Acylated insulin
US6703017B1 (en) *	1994-04-28	2004-03-09	Ixion Biotechnology, Inc.	Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US5461031A (en)	1994-06-16	1995-10-24	Eli Lilly And Company	Monomeric insulin analog formulations
US5646242A (en)	1994-11-17	1997-07-08	Eli Lilly And Company	Selective acylation of epsilon-amino groups
US5693609A (en)	1994-11-17	1997-12-02	Eli Lilly And Company	Acylated insulin analogs
US6251856B1 (en)	1995-03-17	2001-06-26	Novo Nordisk A/S	Insulin derivatives
EP0871665B1 (en)	1995-03-17	2003-07-23	Novo Nordisk A/S	Insulin derivatives
US6451970B1 (en)	1996-02-21	2002-09-17	Novo Nordisk A/S	Peptide derivatives
US5905140A (en)	1996-07-11	1999-05-18	Novo Nordisk A/S, Novo Alle	Selective acylation method
US5898067A (en)	1997-02-07	1999-04-27	Novo Nordisk A/S	Crystallization of proteins
JP3764174B2 (ja)	1997-03-20	2006-04-05	ノボノルディスクアクティーゼルスカブ	肺用組成物において使用するための亜鉛非含有のインスリン結晶
US6444641B1 (en)	1997-10-24	2002-09-03	Eli Lilly Company	Fatty acid-acylated insulin analogs
JP2001521004A (ja)	1997-10-24	2001-11-06	イーライ・リリー・アンド・カンパニー	脂肪酸−アシル化インスリン類似体
US6451762B1 (en)	1997-10-24	2002-09-17	Novo Nordisk A/S	Aggregates of human insulin derivatives
PL195845B1 (pl)	1997-10-24	2007-10-31	Novo Nordisk As	Rozpuszczalny w wodzie agregat pochodnych insuliny
ZA989744B (en)	1997-10-31	2000-04-26	Lilly Co Eli	Method for administering acylated insulin.
CO4970787A1 (es)	1997-12-23	2000-11-07	Lilly Co Eli	Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
DE69924232D1 (de)	1998-01-09	2005-04-21	Novo Nordisk As	Stabilisierte insulin-zubereitungen
EP1086130A1 (en)	1998-06-12	2001-03-28	Kings College London	Insulin analogue
AU5454200A (en)	1999-06-29	2001-01-31	Eli Lilly And Company	Protamine-free insoluble acylated insulin compositions
WO2001093837A2 (en)	2000-06-08	2001-12-13	Eli Lilly And Company	Protein powder for pulmonary delivery
DE10114178A1 (de)	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
JP2005526009A (ja)	2001-12-02	2005-09-02	ノボ　ノルディスク　アクティーゼルスカブ	新規グルコース依存性インスリン
CZ2004710A3 (cs)	2001-12-20	2005-02-16	Eli Lilly And Company	Inzulínová sloučenina s protrahovaným účinkem
AU2003208316A1 (en)	2002-03-13	2003-09-22	Novo Nordisk A/S	Minimising body weight gain in insulin treatment
US20040138099A1 (en)	2002-11-29	2004-07-15	Draeger Eberhard Kurt	Insulin administration regimens for the treatment of subjects with diabetes
US20060217290A1 (en)	2003-04-29	2006-09-28	Kohn Wayne D	Insulin analogs having protracted time action
US20060183667A1 (en)	2003-07-11	2006-08-17	Novo Nordisk A/S	Stabilised insulin compositions
EP1644411A2 (en)	2003-07-11	2006-04-12	Novo Nordisk A/S	Stabilised insulin compositions
EP2107069B1 (en)	2003-08-05	2013-01-16	Novo Nordisk A/S	Novel insulin derivatives
EP1660047B1 (en)	2003-08-13	2013-11-27	Biocon Limited	Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
EP1687428A1 (en)	2003-11-14	2006-08-09	Novo Nordisk A/S	Processes for making acylated insulin
JP5697831B2 (ja)	2003-12-03	2015-04-08	ノヴォノルディスクアー／エス	単鎖インシュリン
WO2006008238A1 (en)	2004-07-16	2006-01-26	Novo Nordisk A/S	Method for selective acylation
CN103223160B (zh)	2004-07-19	2015-02-18	比奥孔有限公司	胰岛素-低聚物共轭物,制剂及其用途
ES2438145T3 (es)	2005-02-02	2014-01-16	Novo Nordisk A/S	Nuevos derivados de insulina
JP5410020B2 (ja)	2005-02-02	2014-02-05	ノヴォノルディスクアー／エス	インスリン誘導体
JP2008533100A (ja)	2005-03-18	2008-08-21	ノボノルディスクアクティーゼルスカブ	Ｐｅｇ化された単鎖インスリン
US20090074882A1 (en)	2005-12-28	2009-03-19	Novo Nordisk A/S	Insulin compositions and method of making a composition
JP5202338B2 (ja)	2006-02-27	2013-06-05	ノボ・ノルデイスク・エー／エス	新規インシュリン誘導体
US8796205B2 (en)	2006-05-09	2014-08-05	Novo Nordisk A/S	Insulin derivative
BRPI0712041A2 (pt)	2006-05-09	2011-12-27	Novo Nordisk As	derivado de insulina
EP2076242B8 (en)	2006-07-27	2013-02-20	Nektar Therapeutics	Aerosolizable formulation comprising insulin for pulmonary delivery
JP5550338B2 (ja)	2006-07-31	2014-07-16	ノボ・ノルデイスク・エー／エス	ペグ化持続型インスリン
HUE029512T2 (en) *	2006-09-22	2017-03-28	Novo Nordisk As	Protease Resistant Insulin Analogs
WO2008145721A2 (en)	2007-06-01	2008-12-04	Novo Nordisk A/S	N-terminal modification of polypeptides for protection against degradation by aminopeptidases
JP5552046B2 (ja)	2007-06-13	2014-07-16	ノボ・ノルデイスク・エー／エス	インスリン誘導体を含有する薬学的製剤
WO2009015456A1 (en)	2007-07-30	2009-02-05	Generex Pharmaceuticals Inc.	Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray
ES2548304T3 (es)	2007-08-15	2015-10-15	Novo Nordisk A/S	Análogos de la insulina que contienen una fracción acilo y alquilenglicol
US8710000B2 (en)	2007-11-08	2014-04-29	Novo Nordisk A/S	Insulin derivative
WO2009063072A2 (en)	2007-11-16	2009-05-22	Novo Nordisk A/S	Pharmaceutical compositions containing insulin and an insulinotropic peptide
ES2632504T3 (es)	2007-11-20	2017-09-13	Ambrx, Inc.	Polipéptidos de insulina modificados y sus usos
JP5762001B2 (ja)	2008-03-14	2015-08-12	ノボ・ノルデイスク・エー／エス	プロテアーゼ安定化インスリンアナログ
WO2009115469A1 (en) *	2008-03-18	2009-09-24	Novo Nordisk A/S	Protease stabilized, acylated insulin analogues
JP5591243B2 (ja)	2008-09-12	2014-09-17	ノボ・ノルデイスク・エー／エス	ペプチド又はタンパク質のアシル化の方法
KR20110085985A (ko)	2008-10-30	2011-07-27	노보 노르디스크 에이/에스	하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료
CN102245624B (zh)	2008-12-19	2016-08-10	印第安纳大学研究及科技有限公司	基于酰胺的胰岛素前药
EP2448962B1 (en)	2009-06-30	2016-10-19	Novo Nordisk A/S	Insulin derivatives
SG178195A1 (en) *	2009-07-31	2012-03-29	Sanofi Aventis Deutschland	Long acting insulin composition
JP6249773B2 (ja)	2010-05-10	2017-12-20	ノヴォノルディスクアー／エス	インスリン−亜鉛錯体の調製方法
KR20130036290A (ko) *	2010-06-23	2013-04-11	노보 노르디스크 에이/에스	추가 이황화 결합을 함유하는 인슐린 유도체
WO2011161124A1 (en)	2010-06-23	2011-12-29	Novo Nordisk A/S	Insulin analogues containing additional disulfide bonds
EP2595647A1 (en)	2010-07-20	2013-05-29	Novo Nordisk A/S	N-terminal modified fgf21 compounds
US9260503B2 (en) *	2011-06-15	2016-02-16	Novo Nordisk A/S	Multi-substituted insulins
KR20150021011A (ko)	2011-10-27	2015-02-27	케이스 웨스턴 리저브 유니버시티	초고도 농축된, 속효성 인슐린 유사체 제형

2015
- 2015-02-25 AR ARP150100559A patent/AR099569A1/es unknown
- 2015-02-26 US US15/121,206 patent/US10040839B2/en active Active
- 2015-02-26 RS RS20201399A patent/RS61137B1/sr unknown
- 2015-02-26 CN CN201580010746.3A patent/CN106459171B/zh active Active
- 2015-02-26 PL PL15707102T patent/PL3110840T3/pl unknown
- 2015-02-26 TW TW104106145A patent/TWI686403B/zh not_active IP Right Cessation
- 2015-02-26 WO PCT/EP2015/053989 patent/WO2015128403A2/en not_active Ceased
- 2015-02-26 HU HUE15707102A patent/HUE051355T2/hu unknown
- 2015-02-26 BR BR112016017193A patent/BR112016017193A2/pt not_active Application Discontinuation
- 2015-02-26 MX MX2016010899A patent/MX368387B/es active IP Right Grant
- 2015-02-26 ES ES15707102T patent/ES2831848T3/es active Active
- 2015-02-26 AU AU2015222135A patent/AU2015222135B2/en not_active Ceased
- 2015-02-26 JP JP2016554498A patent/JP6580583B2/ja active Active
- 2015-02-26 PT PT157071028T patent/PT3110840T/pt unknown
- 2015-02-26 SI SI201531416T patent/SI3110840T1/sl unknown
- 2015-02-26 KR KR1020167024826A patent/KR20160125988A/ko not_active Withdrawn
- 2015-02-26 EP EP15707102.8A patent/EP3110840B1/en active Active
- 2015-02-26 DK DK15707102.8T patent/DK3110840T3/da active
- 2015-02-26 HR HRP20201732TT patent/HRP20201732T1/hr unknown
- 2015-02-26 CA CA2941103A patent/CA2941103A1/en not_active Withdrawn
- 2015-02-26 RU RU2016135543A patent/RU2684456C2/ru active
2016
- 2016-07-13 IL IL246757A patent/IL246757B/en active IP Right Grant
- 2016-08-21 SA SA516371705A patent/SA516371705B1/ar unknown

Also Published As

Publication number	Publication date
AU2015222135A1 (en)	2016-07-28
WO2015128403A3 (en)	2015-12-10
EP3110840B1 (en)	2020-10-21
EP3110840A2 (en)	2017-01-04
CN106459171B (zh)	2020-12-15
JP6580583B2 (ja)	2019-09-25
JP2017508741A (ja)	2017-03-30
HUE051355T2 (hu)	2021-03-01
MX368387B (es)	2019-10-01
RU2016135543A3 (da)	2018-08-30
PL3110840T3 (pl)	2021-04-06
TW201620930A (zh)	2016-06-16
RU2016135543A (ru)	2018-03-30
PT3110840T (pt)	2020-11-26
AR099569A1 (es)	2016-08-03
CN106459171A (zh)	2017-02-22
US20170008945A1 (en)	2017-01-12
ES2831848T3 (es)	2021-06-09
RU2684456C2 (ru)	2019-04-09
IL246757A0 (en)	2016-08-31
WO2015128403A2 (en)	2015-09-03
SI3110840T1 (sl)	2020-12-31
TWI686403B (zh)	2020-03-01
CA2941103A1 (en)	2015-09-03
IL246757B (en)	2020-04-30
KR20160125988A (ko)	2016-11-01
RS61137B1 (sr)	2020-12-31
HRP20201732T1 (hr)	2020-12-25
US10040839B2 (en)	2018-08-07
SA516371705B1 (ar)	2019-10-08
BR112016017193A2 (pt)	2017-10-03
AU2015222135B2 (en)	2018-12-20
MX2016010899A (es)	2016-11-18

Publication	Publication Date	Title
IL258402B1 (en)	2023-03-01	Electroporation for obesity or diabetes treatment
SI3110840T1 (sl)	2020-12-31	Analog humanega insulina A22K, DESB27, B29R, DES B30, aciliran na epsilon položaju lizina 22
DK3240612T3 (da)	2021-01-18	Fremgangsmåder til behandling af nethindesygdomme
LT2916860T (lt)	2020-07-10	Diabeto gydymui skirta kompozicija, apimanti oksintomodulino analogą
DK3258919T4 (da)	2022-11-21	Næsepulverformulering til behandling af hypoglykæmi
DK3390390T3 (da)	2021-12-06	Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3097085T3 (da)	2020-10-26	Benzoxazinonderivater til behandling af hudsygdomme
DK3554534T3 (da)	2021-08-23	Farmaceutisk sammensætning omfattende insulin
MA40911A (fr)	2017-09-12	Compositions de piégeage d'oxygène ne nécessitant pas de période d'induction
IL248779A0 (en)	2017-01-31	Pharmaceutical compositions for treating infectious diseases
DK3241551T3 (da)	2020-11-09	Farmaceutisk sammensætning til behandling af kræft, indeholdende lactatmetalsalt
DK3302573T3 (da)	2019-11-11	Sammensætning til behandlingen af hjernelæsioner
GB2541840B (en)	2017-09-06	Ophthalmic composition for the treatment of ocular infection
IL258137A (en)	2018-05-31	HIV treatment measures
DK3506956T3 (da)	2021-06-14	Lægemiddel, særlig til behandling af fistler
DK3325027T3 (da)	2024-01-02	Medicinsk implantat
DK3096775T3 (da)	2023-03-27	SOCS-mimetika til behandling af sygdomme
IL251392B (en)	2020-11-30	Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
IL257930A (en)	2018-05-31	A composition for use in the treatment of intervertebral disc-related pain
DK3395350T3 (da)	2022-07-11	Lægemiddel til behandling af hjerneinfarkt
EP3369419C0 (en)	2024-08-28	COMPOSITION FOR THE TREATMENT OF DIABETES
ZA201804588B (en)	2019-09-25	Pharmaceutical formulations for the treatment of diabetes
LT3519050T (lt)	2023-08-25	Kompozicijos, skirtos oftalmologinių būklių gydymui
EP3485888A4 (en)	2020-03-11	DRUG COMPOSITION FOR INHALATION
PL3359672T3 (pl)	2020-12-28	Biologiczna kontrola wirusów roślinnych